 BELTSVILLE, Md., Oct. 07, 2021 GLOBE NEWSWIRE -- NextCure, Inc. Nasdaq: NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of preclinical data in the online journal Frontiers in Immunology, which indicate that collagen fragments produced in cancer can mediate T cell suppression through LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells. This immune suppression could be reversed by LAIR-2, a natural decoy of LAIR-1, and NC410, a LAIR-2 fusion protein. NC410 is currently being evaluated in a Phase 12 clinical trial in patients with advanced or metastatic solid tumors and is a first-in-class immunomedicine designed to block LAIR-1-mediated immune suppression. 